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Introduction
Vaccination is one of the great medical success stories, utilizing immune system. Vac-
cine requires the induction of antigen-specific, nontoxic, long-lived immune protec-
tion against diseases [1,2]. Since dendritic cells (DCs) were discovered and demon-
strated to be the key inducers and regulators of immune responses, DCs became at-
tractive tools for vaccine and immunotherapy [3-5]. Use of DCs for vaccination gave 
rise to the possibility of inducing strong T cell immunity to fight against cancer and in-
fection, such as human immunodeficiency virus (HIV), and thus overcoming the limi-
tation of conventional vaccines which rely largely on the induction of protective anti-
body responses [6]. 
 Furthermore, the recent findings that classical DCs effectively control the tolerance 
of T cells expanded the potential of DC-based vaccines, beyond conventional immu-
nogenic goals, to preventing or treating any disease related to immune system’s abnor-
malities [2,5-7]. Especially, the late Ralph Steinman and his colleagues have pioneered 
the method of targeting antigen proteins to the endocytic receptors on DCs in vivo 
and thus efficiently exploiting the function of DCs as immunologically versatile regula-
tors [2]. 
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Dendritic cells (DCs) are professional antigen-presenting cells capable of initiating and regu-
lating innate and adaptive immunity. The development of effective ways to produce a large 
number of DCs in laboratories made the use of DCs available in various vaccine approaches. 
Compared to conventional vaccines, focused on protective antibody responses, DC vaccines 
emphasize protective T cell immunity but might elicit strong antibody responses as well. In ad-
dition, the recent discoveries of functionally distinct DC subsets in various organs and tissues 
are likely to increase the potential of exploiting DCs in vaccines and immunotherapy. Vac-
cines composed of DCs generated ex vivo, pulsed with antigens, and matured prior to being re-
infused to the body have been widely tried clinically but resulted in limited success due to vari-
ous obstacles. In this review, new approaches that protein vaccines are selectively targeted 
to the endocytic C-type lectin receptors on surface of DCs in vivo are discussed. 
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Dendritic Cells
DCs are specialized populations of leukocytes essential for 
controlling the immune system to tolerate or react properly 
against a vast number of different challenges it encounters. 
As professional antigen presenting cells (APCs) and sentinels 
of the immune system, DCs are located largely in the T-cell 
areas of lymphoid tissues and also in most tissues including 
body surfaces where they come across and seize antigens fol-
lowed by migration to lymphoid organs. 
 The versatile roles of DCs in both immunogenic and tolero-
genic functions can be explained by the transforming process 
of DCs known as maturation [2,3,7]. In homeostatic settings, 
immature DCs can actively induce T cell tolerance through 
induction of selection, anergy, or deletion of T cells including 
regulatory T (Treg) cells during development in thymus and 
periphery. Upon activation via signals from various receptors 
for antigens, cytokines, pathogen-associated molecular pat-
terns, or damage-associated molecular patterns, DCs become 
mature by changing into an immunogenic phenotype and 
capable of inducing the activation of T cells [1-3]. 
Vaccination with Ex Vivo-Generated DCs
Provenge from Dendreon is the first Food and Drug Adminis-
tration-approved autologous cellular immunotherapy for the 
treatment of advanced metastatic castrate resistant prostate 
cancer. Provenge is composed of not only DCs but also other 
autologous peripheral blood mononuclear cells, pulsed with 
granulocyte-macrophage colony-stimulating factor-fused 
prostatic acid phosphatase, a prostate self antigen, and incu-
bated for 36 to 44 hours prior to being reinfused to the pa-
tient, which could help extend survival for a few months [8]. 
Clinical trials of various DC vaccines generated ex vivo and 
pulsed with cancer cells or antigens have proved safe and im-
munogenic against the cancers but only resulted in limited 
success [9]. There exist significant problems in current vac-
cines utilizing ex vivo-derived DCs, such as the practical diffi-
culties of logistics and organization and the optimization of 
methods to overcome the limited efficacy likely due to their 
inefficiency in migration and antigen presentation following 
reinfusion to the body. 
C-type Lectin Receptors on DCs
C-type lectin receptors (CLRs) have special importance for 
DCs to function as professional APCs. Compared to other 
pattern recognition receptors (PRRs) such as Toll-like recep-
tors (TLRs), NOD-like receptors, and RIG-I-like receptors, 
CLRs are composed of a large number of members which 
can recognize a broad range of their glycosylated ligand mol-
ecules and microbes. Upon recognition and binding of their 
ligand antigens, CLRs can take up and clear the antigens from 
environment and may generate signals for DCs to become 
mature. Especially, a variety of CLRs are highly expressed on 
DC surface where they perform as efficient endocytic recep-
tors for antigens. This is important for DCs to function as prin-
cipal sentinels and APCs of the immune system to capture 
and present antigens and thus to mount or tolerize adaptive 
immune responses to the antigens. 
 In addition to their functional roles, CLRs are useful in dis-
tinguishing the different subsets of DCs in various tissues and 
organs. In immune cells, mainly 2 groups of CLRs are found: 
1) type I transmembrane proteins with multi-lectins or mul-
tiple carbohydrate recognition domains (CRDs), such as CD205/ 
DEC205, CD206/MMR, etc., and 2) type II transmembrane 
proteins with a single CRD, such as CD209/DC-SIGN, CD207/ 
langerin, CD303/BDCA-2, Dectin, etc. Such CLRs as CD303, 
CD207, and CD205 are routinely used to identify and purify 
distinctive subsets of DCs in blood, skin, and lymphoid tissues. 
Targeting vaccine proteins to CD205 on DCs in vivo 
CD205, also known as DEC205 (a type I transmembrane pro-
tein containing deca lectin domains with molecular weight of 
205 kDa), is the first identified DC-specific receptor. A mono-
clonal antibody (mAb) named NLDC145 was shown to spe-
cifically label DCs in lymphoid tissues [10], and the cDNA en-
coding the protein reactive to NLDC145 was cloned and nam-
ed DEC205 [11]. Studies revealed that, when bound with sur-
rogate ligands, CD205 could function as an efficient endocyt-
ic receptor that delivered the ligands to antigen processing 
pathways for the presentation on both class I and II MHC mol-
ecules [11-13]. Recently, a class of oligonucleotides with non-
methylated cytosine-guanosine (CpG) motifs were identified 
as ligands of CD205 [14], which implies that CD205 might be 
an endocytic receptor for both antigen and maturation stim-
ulus in DCs. 
 When a peptide antigen was fused to a recombinant anti-
CD205 mAb and delivered to CD205 on DCs in mouse, the 
responding T cells become eliminated or unresponsive to a 
further re-stimulation of the same peptide [15,16], resulting 
in tolerance of antigen-specific T cells. This proves that DCs 
 Chae Gyu Park • Dendritic cell targeted vaccine
151http://www.ecevr.org/http://dx.doi.org/10.7774/cevr.2014.3.2.149
in vivo actively establish T cell tolerance by presenting anti-
gens from self and environment during the steady state. In 
contrast, antigen-conjugated anti-CD205 mAb co-injected 
with anti-CD40 antibody induced strong and lasting T cell 
immunity against the antigen [13,15,17]. Therefore, CD205 
could also become a target on DCs in vivo exploited for anti-
body-based vaccine delivery. 
 Injected whether intravenously or subcutaneously, the anti-
CD205 mAb fused with antigen was targeted to DCs in spleen 
and lymph nodes within 30 minutes [17]. With adjuvant, such 
as anti-CD40 and/or PRR agonist, anti-CD205 mAb-conju-
gated antigens could generate antigen-specific T cell respons-
es with much higher efficiency, i.e., at least 100 to 1,000 fold 
more than unconjugated and control mAb-conjugated anti-
gens [6,17]. Likewise, animals immunized with anti-CD205-
conjugated antigens demonstrated that vaccines targeted to 
DCs in vivo produced the strong and long-lived memory re-
sponses of antigen-specific T cells [17,18]. In addition to the 
improved intensity and durable memory, targeting antigen to 
CD205 on DCs was able to generate the response of diverse T 
cell repertoires against various peptides from the antigen, ef-
ficiently presented by the MHC molecules of different haplo-
types and individuals [18,19]. 
 The protective immunity induced by the CD205-targeted 
vaccines was tested by various infection models. Mice chal-
lenged with either vaccinia virus or Yersinia pestis via airway 
route were effectively protected following vaccination with 
protective antigens conjugated to anti-CD205 mAb [18,20]. In 
those mice, the protective immunity generated by DC-target-
ed vaccine antigen was attributed to the efficient induction of 
antigen-specific helper T cells, accompanied by strong hu-
moral immunity, i.e., high antibody titers against the antigen. 
Although the conventional, non-targeted vaccines immuniz-
ed with alum adjuvant also induced high titers of antibodies 
and exhibited effective protection, only the DC-targeted vac-
cines were able to generate strong and durable T cell respons-
es, implying that DC-targeted vaccines might be superior in 
the long run. 
Development of Clinical Vaccine Targeted to 
Human CD205 
The first protein antigen of pathogens selected for CD205-tar-
geted clinical vaccine was Gag protein of HIV-1, because the 
T cell immunity to Gag showed a protective potential [6]. The 
p41 fragment of Gag p55 was engineered to fuse with the C-
terminus of heavy chain in anti-CD205 or control mAbs. The 
recombinant proteins of unconjugated and mAb-conjugated 
p41 were expressed in mammalian cell-lines such as HEK293T 
or CHO cells, secreted into culture media, and purified. Be-
cause the purified Gag p41 protein appeared to form aggre-
gation, the p24 fragment of Gag p41 was also generated, ex-
pressed, purified, and then compared with p41. As shown in 
Fig. 1, the majority of p41 protein, even in cell culture media 
prior to purification, was aggregated and in complex with 
other molecules. However, the p24 protein was in a mono-
meric, soluble form when expressed from mammalian cells 
(Fig. 1). Therefore, to optimize the delivery of antigen to DCs 
and to rule out the artifact from aggregation, p24 was chosen 
as the Gag antigen for HIV vaccine. 
 To generate immunogenic DCs effectively in vivo, different 
types of stimulators were tested as adjuvant for the CD205-
targeted p24 vaccination. In mice, amongst diverse agonists 
of different innate immune receptors, poly IC, a synthetic dou-
ble-stranded RNA ligand to TLR3 and MDA-5, and its stabi-
lized clinical version, poly ICLC or Hiltonol, were found most 
effective in stimulating the DCs targeted with p24 and thus 
inducing both T and B cell immunity via systemic interferon 
responses [21,22]. In humans, the treatment of poly ICLC in-
duced the various pathways of innate immune responses 
broadly and efficiently, i.e., quite similarly to the highly effec-
tive yellow fever vaccine [23]. Therefore, poly ICLC was cho-
sen for the adjuvant in clinical studies of the first vaccine tar-
geted to DCs in vivo [6]. 
 To translate the preclinical studies of CD205-targeted DC 
vaccines into humans, a series of new anti-human CD205 
mAbs were produced and tested. Due to the large size of CD-
205, early attempts to immunize animals with the limited siz-
es of CD205 protein fragments were able to generate only a 
few anti-human CD205 mAbs [24,25]. Therefore, a new effort 
was pursued to generate a large number of mAbs against the 
diverse epitopes in human CD205, for the selection of an an-
ti-human CD205 mAb used in clinical studies. To this end, 
the extracellar domain of full-length CD205 protein was pro-
duced and used to immunize two different kinds of mice: 
mice carrying not mouse but human immunoglobulin genes 
[26] and mice deficient of CD205 gene, i.e., CD205 knockout 
mice [27]. Especially, from a single hybridoma fusion, the lat-
ter produced a large number, i.e., over 400 of anti-human 
CD 205 mAbs, many of which were verified to bind not only 
human CD205 but also CD205 of mouse and other mammals 
[27]. This cross-species reactivity of anti-human CD205 mAbs 
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Fig. 1. Analyses of human immunodeficiency virus Gag proteins ex-
pressed from mammalian CHO cells. (A) Soluble, FLAG-tagged Gag 
p41 and p24 proteins were produced into culture media from the 
stably transfected CHO cells, followed by anti-FLAG affinity purifica-
tion. Left panel: Five micrograms each of purified p41 and p24 was 
subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel elec-
trophoresis with/without (+/-) treatment of β-mercaptoethanol (BME) 
and boiling at 100°C for 5 minutes (Boiling). After electrophoresis, 
the gel was visualized with Coomassie blue stain. Aggregates on 
the border between stacking and resolving gels and on the bottom of 
loading wells are detected from the purified p41 without BME & Boil-
ing. Right panel: Zero point five microgram each of purified p41 and 
Coomassie blue stain
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p24 was subjected to SDS-polyacrylamide gel electrophoresis with/without BME & Boiling. After electrophoresis, the gel was transferred onto 
polyvinylidene difluoride (PVDF) membrane, blotted with anti-Gag antibody, and visualized with chemiluminescent reagent. Aggregates with 
high molecular weight are detected from the purified p41 without BME & Boiling. (B) Culture supernatants from stably transfected CHO cells 
expressing soluble, FLAG-tagged Gag p41 and p24 proteins were analyzed. Five microliters each of cell culture supernatants was subjected to 
SDS-polyacrylamide gel electrophoresis with/without BME & Boiling. After electrophoresis, the gel was transferred onto PVDF membrane, blot-
ted with anti-Gag antibody, and visualized with chemiluminescent reagent. Aggregates with high molecular weight are detected from the cell 
culture supernatant of p41 without BME & Boiling.
has advantage that those mAbs can deliver the vaccines to 
DCs in humans as well as in mice and other animals. This 
will solve a need to generate animal models that express hu-
man CD205 in their DCs. However, fully human anti-human 
CD205 mAbs can be produced from the former mice [26], not 
requiring the further process to humanize mouse anti-human 
CD205 mAbs generated in the case of the latter mice. 
 From the mice with human immunoglobulin genes, 6 hu-
man anti-human CD205 mAbs were generated. Among those, 
mAbs cross-reactive to monkey CD205 were selected and com-
pared for their vaccine-targeting capacities with an existing 
anti-human CD205 mAb [26]. For this job, a transgenic (Tg) 
mouse was generated to carry a full-length human CD205 
cDNA under CD11c promoter, thus expressing the human 
CD205 endocytic receptor on mouse DCs. Then, anti-human 
CD205 mAb named 3G9 was determined most efficient to in-
duce immune responses in the human CD205 Tg mice as well 
as in human peripheral blood cell cultures [26]. Therefore, 
mAb 3G9 was chosen to conjugate HIV Gag p24 and put for-
ward to the first clinical trial of DC-targeting vaccines [6]. 
Targeting Vaccine Proteins to Other CLRs on 
DCs In Vivo 
It had been shown that delivering an antigen to different sub-
sets of DCs in vivo resulted in different immune responses. 
Antigen targeted to DCIR2-positive DCs stimulated CD4 T 
cells preferentially while CD205-positive DCs did CD8 T cells 
[28]. The difference of ability between those subsets of DCs 
was attributed to the differential expression of genes involved 
in the different pathways of antigen processing and presenta-
tion. When the protective immunity to an infection relied 
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heavily on antibody response, the vaccine protein targeted to 
DCIR2, compared to CD205, on DCs in vivo induced higher 
antibody titers and thus achieved better protection [20]. 
 Besides classical DCs in steady state, the role of a DC po-
pulation(s) derived from monocytes in vivo had been sug-
gested by animal models of various infections and by the mo-
nocyte-to-DC differentiation in vitro. DC-SIGN or CD209a 
was recently identified as a marker of monocyte-derived DCs 
in mouse lymph nodes during inflammation caused by Gram-
negative bacteria and TLR4 agonists [29]. Upon administra-
tion of Gram-negative bacteria or TLR4 agonist like LPS, mono-
cytes were mobilized to the T cell area of lymph nodes and 
fully differentiated to functional DCs expressing CD209a. Due 
to the newly generated mAbs with high affinities to CD209a 
[30], monocyte-derived inflammatory DCs could be detected 
in vivo [29]. With TLR4 agonist, targeting CD209a-positive DCs 
generated stronger antigen-specific T cell responses than tar-
geting CD205-positive DCs, which implies that monocyte-
derived inflammatory DCs might be better targets of vaccine 
delivery for the induction of protective immunity against mi-
crobial pathogens. 
 
Future of Targeting Vaccines to DCs In Vivo 
Now, beginning with targeting vaccines to CD205-positve 
DCs in vivo, various CLRs marking different subsets of DCs 
are being investigated for the delivery target of vaccine anti-
gens in vivo. As seen in the cases of CD205, CD209a, and 
DCIR2, same antigens targeted to different subsets of DCs 
under distinct environments resulted in varied immune re-
sponses of T cells as well as B cells. Likely, there also exist 
more of unknown subsets of DCs with novel functions [31], 
yet to be found and targeted with vaccines in the future. Fol-
lowing characterization of the differences in the function of 
each vaccine targeted to a different subset of DCs in vivo, the 
differentially targeted vaccines could be combined to boost 
their activities or to generate a novel effect. In addition, the 
DC-targeted vaccine with combination of another vaccine in 
different platforms may intensify the immunogenicity of both 
vaccines, as shown in the combination of DC-targeting and 
attenuated viral vaccines [32]. 
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